Page 1 | Search Results | Diabetes | American Diabetes Association

1-20 of 89

Sort by

Sort Order Select

Journal Articles

Glucagon Clearance Is Decreased in Chronic Kidney Disease but Preserved in Liver Cirrhosis

Magnus F.G. Grøndahl, Andreas H. Lange, Malte P. Suppli, Jonatan I. Bagger, Mira Thing, Lise L. Gluud, Dea H. Kofod, Mads Hornum, Gerrit van Hall, Samuel A.J. Trammell, Trisha J. Grevengoed, Bolette Hartmann, Jens J. Holst, Tina Vilsbøll, Mikkel B. Christensen, Asger B. Lund, Filip K. Knop

Diabetes 2024;73(10):1641–1647

https://doi.org/10.2337/db24-0305

Published: 25 July 2024

View article titled, Glucagon Clearance Is Decreased in Chronic Kidney Disease but Preserved in Liver Cirrhosis

Meeting Abstracts

121-OR: Safety, Tolerability, and Metabolic Effects of Once-Weekly GL0034 (Utreglutide) in Individuals with Obesity—A Multiple Ascending Dose Study

RAJAMANNAR THENNATI, VINOD S. BURADE, MUTHUKUMARAN NATARAJAN, PRADEEP SHAHI, RAVISHANKARA NAGARAJA, SUDEEP K. AGRAWAL, THIERRY DUVAUCHELLE, ADOLFO GARCIA-OCANA, GUY A. RUTTER, RICHARD E. PRATLEY, BERNARD THORENS, TINA VILSBØLL

Diabetes 2024;73(Supplement_1):121-OR

https://doi.org/10.2337/db24-121-OR

Published: 14 June 2024

View article titled, 121-OR: Safety, Tolerability, and Metabolic Effects of Once-Weekly GL0034 (Utreglutide) in Individuals with Obesity—A Multiple Ascending Dose Study

Meeting Abstracts

909-P: Impact of SGLT2 Inhibition on Glucosuria in HNF1A-MODY

HENRIK MAAGENSEN, JOHANNE S. JENSEN, STINE OFFERSGAARD HØYERUP, ANNE CATHRINE B. THUESEN, JESPER KROGH, PETER ROSSING, TORBEN HANSEN, FILIP K. KNOP, SOFIE HAEDERSDAL, TINA VILSBØLL

Diabetes 2024;73(Supplement_1):909-P

https://doi.org/10.2337/db24-909-P

Published: 14 June 2024

View article titled, 909-P: Impact of SGLT2 Inhibition on Glucosuria in HNF1A-MODY

Meeting Abstracts

840-P: Efficacy and Safety of Once-Weekly Insulin Icodec vs. Once-Daily Basal Insulin in Type 2 Diabetes according to Baseline Glucagon-Like Peptide 1 Receptor Agonist Use—ONWARDS 1–5

TINA VILSBØLL, KATRINE O. BANGSGAARD, ARIEL FU, MONIKA KELLERER, STINNE B. SØGAARD, RONALD GOLDENBERG

Diabetes 2024;73(Supplement_1):840-P

https://doi.org/10.2337/db24-840-P

Published: 14 June 2024

View article titled, 840-P: Efficacy and Safety of Once-Weekly Insulin Icodec vs. Once-Daily Basal Insulin in Type 2 Diabetes according to Baseline Glucagon-Like Peptide 1 Receptor Agonist Use—ONWARDS 1–5

Meeting Abstracts

116-OR: GL0034 (Utreglutide), a Novel GLP-1RA, Increases Liver FGF-21 and Demonstrates Significant Efficacy on Weight Loss, HbA1c, and Triglycerides in db/db Mice

RAJAMANNAR THENNATI, VINOD S. BURADE, MUTHUKUMARAN NATARAJAN, ADOLFO GARCIA-OCANA, GUY A. RUTTER, RICHARD E. PRATLEY, BERNARD THORENS, TINA VILSBØLL

Diabetes 2024;73(Supplement_1):116-OR

https://doi.org/10.2337/db24-116-OR

Published: 14 June 2024

View article titled, 116-OR: GL0034 (Utreglutide), a Novel GLP-1RA, Increases Liver FGF-21 and Demonstrates Significant Efficacy on Weight Loss, HbA1c, and Triglycerides in db/db Mice

Journal Articles

Ceramides as Risk Markers for Future Cardiovascular Events and All-Cause Mortality in Long-standing Type 1 Diabetes

Asger Wretlind, Viktor R. Curovic, Tommi Suvitaival, Simone Theilade, Nete Tofte, Signe A. Winther, Tina Vilsbøll, Henrik Vestergaard, Peter Rossing, Cristina Legido-Quigley

Diabetes 2023;72(10):1493–1501

https://doi.org/10.2337/db23-0052

Published: 21 July 2023

View article titled, Ceramides as Risk Markers for Future Cardiovascular Events and All-Cause Mortality in Long-standing Type 1 Diabetes

Meeting Abstracts

178-OR: Better Glycemic Control with Once-Weekly Insulin Icodec vs. Once-Daily Insulin Degludec in Insulin-Naïve Type 2 Diabetes (ONWARDS 3)

ILDIKO LINGVAY, MARISSE ASONG, CYRUS DESOUZA, PIERRE GOURDY, SOUMITRA KAR, ANDRE G. VIANNA, TINA VILSBØLL, SIRI M. VINTHER, YIMING MU

Diabetes 2023;72(Supplement_1):178-OR

https://doi.org/10.2337/db23-178-OR

Published: 23 June 2023

View article titled, 178-OR: Better Glycemic Control with Once-Weekly Insulin Icodec vs. Once-Daily Insulin Degludec in Insulin-Naïve Type 2 Diabetes (ONWARDS 3)

Meeting Abstracts

1651-P: Elevated FGF21 Levels after Total Pancreatectomy and in Response to Single-Dose Glucagon Receptor Antagonism in Humans

MAGNUS F.G. GRØNDAHL, CAROLINE T. JUEL, ASGER LUND, SOFIE HAEDERSDAL, MARIA M. ANDERSEN, JENS S. SVENNINGSEN, MATTHEW GILLUM, BOLETTE HARTMANN, JENS J. HOLST, TINA VILSBØLL, FILIP K. KNOP

Diabetes 2023;72(Supplement_1):1651-P

https://doi.org/10.2337/db23-1651-P

Published: 20 June 2023

View article titled, 1651-P: Elevated FGF21 Levels after Total Pancreatectomy and in Response to Single-Dose Glucagon Receptor Antagonism in Humans

Meeting Abstracts

389-P: Glycemia and Cardiac Arrhythmias in People with Type 1 Diabetes

PER G. HAGELQVIST, ANDREAS ANDERSEN, KAISAR MAYTHAM, CHRISTINE R. ANDREASEN, SUSANNE ENGBERG, TOMMI B. LINDHARDT, JULIE FORMAN, ULRIK PEDERSEN-BJERGAARD, FILIP K. KNOP, TINA VILSBØLL

Diabetes 2023;72(Supplement_1):389-P

https://doi.org/10.2337/db23-389-P

Published: 20 June 2023

View article titled, 389-P: Glycemia and Cardiac Arrhythmias in People with Type 1 Diabetes

Meeting Abstracts

801-P: Short-Acting Exenatide Added Three Times Daily to Insulin Therapy Improves Fatty Liver Index in Type 1 Diabetes

NICKLAS JOHANSEN, THOMAS F. DEJGAARD, ASGER LUND, CASPER K. NIELSEN, TINA VILSBØLL, FILIP K. KNOP

Diabetes 2023;72(Supplement_1):801-P

https://doi.org/10.2337/db23-801-P

Published: 20 June 2023

View article titled, 801-P: Short-Acting Exenatide Added Three Times Daily to Insulin Therapy Improves Fatty Liver Index in Type 1 Diabetes

Meeting Abstracts

766-P: Safety and Tolerability of Once-Weekly GL0034 (Utreglutide) in Healthy Individuals—A Multiple Ascending Dose Study

RAJAMANNAR THENNATI, VINOD S. BURADE, MUTHUKUMARAN NATARAJAN, PRADEEP SHAHI, RAVISHANKARA NAGARAJA, SATISH T. PANCHAL, SUDEEP K. AGRAWAL, BERNARD JANDRAIN, THIERRY DUVAUCHELLE, ADOLFO GARCIA-OCANA, GUY A. RUTTER, RICHARD E. PRATLEY, BERNARD THORENS, TINA VILSBØLL

Diabetes 2023;72(Supplement_1):766-P

https://doi.org/10.2337/db23-766-P

Published: 20 June 2023

View article titled, 766-P: Safety and Tolerability of Once-Weekly GL0034 (Utreglutide) in Healthy Individuals—A Multiple Ascending Dose Study

Meeting Abstracts

765-P: A Single Ascending Dose Study of the Novel GLP-1 Receptor Agonist GL0034 (Utreglutide) in Obese Individuals without Diabetes

Diabetes 2023;72(Supplement_1):765-P

https://doi.org/10.2337/db23-765-P

Published: 20 June 2023

View article titled, 765-P: A Single Ascending Dose Study of the Novel GLP-1 Receptor Agonist GL0034 (Utreglutide) in Obese Individuals without Diabetes

Meeting Abstracts

143-OR: Prevailing Glucose Levels Alter Left Ventricular Contractions Pattern, Myocardial Performance, and Myocardial Energy Efficiency

CHRISTINE R. ANDREASEN, ANDREAS ANDERSEN, PER G. HAGELQVIST, KAISAR MAYTHAM, MORTEN SENGELØV, FILIP K. KNOP, FLEMMING J. OLSEN, TINA VILSBØLL

Diabetes 2023;72(Supplement_1):143-OR

https://doi.org/10.2337/db23-143-OR

Published: 20 June 2023

View article titled, 143-OR: Prevailing Glucose Levels Alter Left Ventricular Contractions Pattern, Myocardial Performance, and Myocardial Energy Efficiency

Journal Articles

Endogenous Glucose-Dependent Insulinotropic Polypeptide Contributes to Sitagliptin-Mediated Improvement in β-Cell Function in Patients With Type 2 Diabetes

Signe Stensen, Lærke S. Gasbjerg, Mette M. Rosenkilde, Tina Vilsbøll, Jens J. Holst, Bolette Hartmann, Mikkel B. Christensen, Filip K. Knop

Diabetes 2022;71(10):2209–2221

https://doi.org/10.2337/db22-0059

Published: 07 July 2022

View article titled, Endogenous Glucose-Dependent Insulinotropic Polypeptide Contributes to Sitagliptin-Mediated Improvement in β-Cell Function in Patients With Type 2 Diabetes

Meeting Abstracts

235-OR: Sustained QTc Prolongation during Recovery from Hypoglycemia in Patients with Type 1 Diabetes

CHRISTINE R. ANDREASEN, ANDREAS ANDERSEN, PER G. HAGELQVIST, JULIUS V. LAURITSEN, SUSANNE ENGBERG, JENS J. HOLST, ULRIK PEDERSEN-BJERGAARD, FILIP K. KNOP, TINA VILSBØLL

Diabetes 2022;71(Supplement_1):235-OR

https://doi.org/10.2337/db22-235-OR

Published: 01 June 2022

View article titled, 235-OR: Sustained QTc Prolongation during Recovery from Hypoglycemia in Patients with Type 1 Diabetes

Meeting Abstracts

182-OR: Clinical Effects of SGLT2 Inhibitors in HNF1A-Diabetes (MODY3) : A Case Series

HENRIK MAAGENSEN, SOFIE HAEDERSDAL, JESPER KROGH, TORBEN HANSEN, FILIP K. KNOP, TINA VILSBØLL

Diabetes 2022;71(Supplement_1):182-OR

https://doi.org/10.2337/db22-182-OR

Published: 01 June 2022

View article titled, 182-OR: Clinical Effects of SGLT2 Inhibitors in HNF1A-Diabetes (MODY3) : A Case Series

Meeting Abstracts

1362-P: Endogenous Glucose-Dependent Insulinotropic Polypeptide Facilitates Postprandial Intestinal Lipid Uptake in Healthy Men, but Not in Patients with Type 2 Diabetes

LÆRKE S. GASBJERG, MADS M. HELSTED, SIGNE STENSEN, LIVA S.L. KROGH, ALEXANDER H. SPARRE-ULRICH, BOLETTE HARTMANN, TINA VILSBØLL, MIKKEL B. CHRISTENSEN, JENS J. HOLST, CHRISTINA CHRISTOFFERSEN, FILIP K. KNOP, METTE M. ROSENKILDE

Diabetes 2022;71(Supplement_1):1362-P

https://doi.org/10.2337/db22-1362-P

Published: 01 June 2022

View article titled, 1362-P: Endogenous Glucose-Dependent Insulinotropic Polypeptide Facilitates Postprandial Intestinal Lipid Uptake in Healthy Men, but Not in Patients with Type 2 Diabetes

Meeting Abstracts

745-P: Short-Acting Exenatide Added Three Times Daily to Insulin Therapy Improves Insulin Sensitivity in Type 1 Diabetes

NICKLAS JOHANSEN, THOMAS F. DEJGAARD, ASGER LUND, TINA VILSBØLL, HENRIK U. ANDERSEN, FILIP K. KNOP

Diabetes 2022;71(Supplement_1):745-P

https://doi.org/10.2337/db22-745-P

Published: 01 June 2022

View article titled, 745-P: Short-Acting Exenatide Added Three Times Daily to Insulin Therapy Improves Insulin Sensitivity in Type 1 Diabetes

Meeting Abstracts

744-P: Effects of a Novel Long-Acting GIP/GLP-1/Glucagon Trireceptor Agonist, HISHS-3001, on HbA1c, Body Weight, and Lipid Metabolism

VINOD S. BURADE, ADOLFO GARCIA-OCANA, RICHARD E. PRATLEY, GUY A. RUTTER, TINA VILSBØLL, BERNARD THORENS, RAJAMANNAR THENNATI

Diabetes 2022;71(Supplement_1):744-P

https://doi.org/10.2337/db22-744-P

Published: 01 June 2022

View article titled, 744-P: Effects of a Novel Long-Acting GIP/GLP-1/Glucagon Trireceptor Agonist, HISHS-3001, on HbA1c, Body Weight, and Lipid Metabolism

Meeting Abstracts

377-P: Exercise-Related Hypoglycemia Induces Hypercoagulable Changes in Patients with Type 1 Diabetes

PER G. HAGELQVIST, ANDREAS ANDERSEN, KAISAR MAYTHAM, SUSANNE ENGBERG, ULRIK PEDERSEN-BJERGAARD, PÄR I. JOHANSSON, FILIP K. KNOP, TINA VILSBØLL

Diabetes 2022;71(Supplement_1):377-P

https://doi.org/10.2337/db22-377-P

Published: 01 June 2022

View article titled, 377-P: Exercise-Related Hypoglycemia Induces Hypercoagulable Changes in Patients with Type 1 Diabetes

NARROW

Glucagon Clearance Is Decreased in Chronic Kidney Disease but Preserved in Liver Cirrhosis

121-OR: Safety, Tolerability, and Metabolic Effects of Once-Weekly GL0034 (Utreglutide) in Individuals with Obesity—A Multiple Ascending Dose Study

909-P: Impact of SGLT2 Inhibition on Glucosuria in HNF1A-MODY

840-P: Efficacy and Safety of Once-Weekly Insulin Icodec vs. Once-Daily Basal Insulin in Type 2 Diabetes according to Baseline Glucagon-Like Peptide 1 Receptor Agonist Use—ONWARDS 1–5

116-OR: GL0034 (Utreglutide), a Novel GLP-1RA, Increases Liver FGF-21 and Demonstrates Significant Efficacy on Weight Loss, HbA1c, and Triglycerides in db/db Mice

Ceramides as Risk Markers for Future Cardiovascular Events and All-Cause Mortality in Long-standing Type 1 Diabetes

178-OR: Better Glycemic Control with Once-Weekly Insulin Icodec vs. Once-Daily Insulin Degludec in Insulin-Naïve Type 2 Diabetes (ONWARDS 3)

1651-P: Elevated FGF21 Levels after Total Pancreatectomy and in Response to Single-Dose Glucagon Receptor Antagonism in Humans

389-P: Glycemia and Cardiac Arrhythmias in People with Type 1 Diabetes

801-P: Short-Acting Exenatide Added Three Times Daily to Insulin Therapy Improves Fatty Liver Index in Type 1 Diabetes

766-P: Safety and Tolerability of Once-Weekly GL0034 (Utreglutide) in Healthy Individuals—A Multiple Ascending Dose Study

765-P: A Single Ascending Dose Study of the Novel GLP-1 Receptor Agonist GL0034 (Utreglutide) in Obese Individuals without Diabetes

143-OR: Prevailing Glucose Levels Alter Left Ventricular Contractions Pattern, Myocardial Performance, and Myocardial Energy Efficiency

Endogenous Glucose-Dependent Insulinotropic Polypeptide Contributes to Sitagliptin-Mediated Improvement in β-Cell Function in Patients With Type 2 Diabetes

235-OR: Sustained QTc Prolongation during Recovery from Hypoglycemia in Patients with Type 1 Diabetes

182-OR: Clinical Effects of SGLT2 Inhibitors in HNF1A-Diabetes (MODY3) : A Case Series

1362-P: Endogenous Glucose-Dependent Insulinotropic Polypeptide Facilitates Postprandial Intestinal Lipid Uptake in Healthy Men, but Not in Patients with Type 2 Diabetes

745-P: Short-Acting Exenatide Added Three Times Daily to Insulin Therapy Improves Insulin Sensitivity in Type 1 Diabetes

744-P: Effects of a Novel Long-Acting GIP/GLP-1/Glucagon Trireceptor Agonist, HISHS-3001, on HbA1c, Body Weight, and Lipid Metabolism

377-P: Exercise-Related Hypoglycemia Induces Hypercoagulable Changes in Patients with Type 1 Diabetes

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

This Feature Is Available To Subscribers Only